Phone: +44 141 899 0081

Archive

Home / Tag: regulatory affairs

Want to know more about our PRIME & EAMS / PIM experience? Meet us at the 2017 DIA EuroMeeting in Glasgow, 29 – 31 March 2017

With the increasing acknowledgement of the need to develop an overarching scheme to enhance support for sponsors developing medicines, tackling unmet medical needs to ensure timely access to beneficial therapies, the EMA launched the PRIME scheme in March 2016. This

Meet us at the DIA 29th Annual EuroMeeting 2017 in Glasgow, 29 – 31 March 2017

  Join top regulators, clinical, safety, and research professionals in health care and drug development. Discuss the biggest challenges, gain new, invaluable insights, and leave inspired to take action. The DIA EuroMeeting goal is to bring together key healthcare stakeholder

Kinesys secures another Promising Innovative Medicine (PIM) Designation from the UK MHRA

Kinesys Consulting last month secured another PIM designation, this time for a new oncology product, on behalf of a US partner. The product, successfully designated as a Promising Innovative Medicine (PIM) by the Medicines and Healthcare Products Regulatory Agency (MHRA), is being developed for the treatment of

Kinesys Consulting secures its first PIM designation from UK MHRA under the EAMS – Early Access to Medicines Scheme

Kinesys Consulting has secured its first PIM designation, for a novel oncology supportive care product, on behalf of a US partner. The product, designated as a Promising Innovative Medicine (PIM) by the Medicines and Healthcare Products Regulatory Agency (MHRA), is being developed for